|
Co-Led by Legend Capital, Top Gene Delivery Enterprise VectorBuilder Secures CNY410mn in Series C Round
HONG KONG, Oct 20, 2022 - (ACN Newswire) - VectorBuilder Biotechnology (Guangzhou) Co., Ltd. (hereinafter referred to as "VectorBuilder"), a top gene delivery enterprise, recently announced the completion of its Series C round with CNY410 million, co-led by Legend Capital. The proceeds will facilitate VectorBuilder in continuously promoting the upgrading and capacity expansion of the gene delivery R&D and production technology platform, further accelerate the global business presence, and boost the R&D of life sciences and genetic medicines.
VectorBuilder was founded by Dr. Bruce Lahn, a world-renowned molecular biologist who was a tenured professor at the University of Chicago and a researcher at Howard Hughes Medical Institute (HHMI). The company provides services such as scientific research and clinical carrier CRO, gene-drug CDMO and gene delivery IP out-licensing, covering the entire field of life science and gene medicine. VectorBuilder has provided more than 1.2 million gene delivery solutions to more than 4,000 scientific research institutes and pharmaceutical companies worldwide, and its gene-drug CRO and CDMO projects are spread all over North America, Europe, Japan and South Korea.
Dr. Bruce Lahn, Founder and Chief Scientist of VectorBuilder, said: "I'd like to take this opportunity to extend my sincere gratitude to investors for the support and trust. Due to a robust technical accumulation and an excellent business model in the gene delivery industry, VectorBuilder enjoys the highest market share in the global gene carrier scientific research market, and we jointly launched the construction of a 45,000-square-meter gene delivery R&D and production base with Guangzhou Development District Investment Group in April 2022. We hope to take this financing round as an opportunity to further accelerate the comprehensive upgrade and optimization of the technology platform and promote the expansion of production capacity and global presence. VectorBuilder has become a pioneer in the entire gene delivery industry chain by empowering basic scientific research and accelerating the clinical application of gene drugs. We believe VectorBuilder will enter thousands of life science laboratories worldwide and become a well-known brand in the field of life science. We will empower the gene-drug industry through core technologies and help China to "overtake" on the genetic drug track. At the same time, we hope to overcome genetic diseases, improve human health, and provide irreplaceable value to the industry and the world."
Jeff Wang, Managing Director of Legend Capital, said: "VectorBuilder is the world's leading gene delivery company, providing full-chain solutions from basic scientific research to clinical application of gene delivery. It is an honor to participate in the future development of VectorBuilder. Dr. Bruce Lahn is an expert in the field of biotechnology innovation, and we are optimistic about VectorBuilder's comprehensive ecological service platform for gene delivery in life science and biomedicine. VectorBuilder has developed the world's first system providing online design, offline production carrier construction and downstream application service, serving thousands of top biopharmaceutical companies and research institutes. We believe VectorBuilder has a promising future as the genetic medicine industry develops."
About Legend Capital
Founded in 2001, Legend Capital is a leading VC&PE investor focusing on the early-stage and growth-stage opportunities in China, with offices across Beijing, Shanghai, Shenzhen, Hong Kong, and Seoul, Korea.
It currently manages USD and RMB funds of over US$10 billion in commitments, and has invested in around 600 companies, covering technology, healthcare, consumer, enterprise service and intelligent manufacturing sectors. Rooted in China, Legend Capital participated in the rise of many world-leading companies by solid investment coverage and systematic post-investment value-add. Over the years, Legend Capital has also become a widely recognized name in bridging key resources in China and overseas through cross-border activities, and a valuable partner to Chinese and overseas investors.
Legend Capital values long-term sustainable investment and incorporates ESG into its long-term development strategy. As a UNPRI signatory since November 2019, Legend Capital is among the first group of top VC/PE firms in China to join the initiative.
For more information, please visit www.legendcapital.com.cn/index_en.aspx and follow us on LinkedIn @Legend Capital (https://www.linkedin.com/company/legend-capital).
Source: Legend Capital
Sectors: BioTech, Healthcare & Pharm, PE, VC & Alternatives
Copyright ©2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network. |